Apogee Therapeutics, Inc. |
Director |
Common Stock |
2.05M |
$76.3M |
$37.26 |
Mar 28, 2024 |
By Fairmount Healthcare Fund II LP |
Viridian Therapeutics, Inc.\DE |
Director, 10%+ Owner |
Common Stock |
3.45M |
$64.6M |
$18.75 |
Sep 13, 2024 |
Fairmount Healthcare Fund II LP |
Oruka Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
2.57M |
$59.2M |
$23.00 |
Sep 11, 2024 |
By Fairmount Healthcare Co-Invest III L.P. |
Cogent Biosciences, Inc. |
Director |
Common Stock |
6.23M |
$46.7M |
$7.50 |
Jun 10, 2024 |
Fairmount Healthcare Fund II LP |
Dianthus Therapeutics, Inc. /DE/ |
Director |
Common Stock |
2.7M |
$32.4M |
$12.00 |
Sep 27, 2024 |
By Fairmount Healthcare Fund II L.P. |
Zenas BioPharma, Inc. |
Director |
Common Stock |
1.89M |
$32.2M |
$17.00 |
Sep 16, 2024 |
By Fairmount Healthcare Fund II LP |
Oruka Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
639K |
$14.7M |
$23.00 |
Sep 11, 2024 |
By Fairmount Healthcare Fund II L.P. |
Dianthus Therapeutics, Inc. /DE/ |
Director |
Pre-Funded Warrants (Right to Buy) |
832K |
$9.99M |
$12.00 |
Jan 22, 2024 |
Indirect |
Oruka Therapeutics, Inc. |
Director, 10%+ Owner |
Series A Non-Voting Convertible Preferred Stock |
160 |
$3.68M |
$23,000.00 |
Sep 11, 2024 |
By Fairmount Healthcare Fund II L.P. |
Spyre Therapeutics, Inc. |
Director |
Common Stock |
4.02M |
$2.85M |
$0.71 |
Apr 25, 2024 |
By Fairmount Healthcare Fund II L.P. |
Apogee Therapeutics, Inc. |
Director |
Common Stock |
51.2K |
$1.91M |
$37.26 |
Mar 28, 2024 |
By Peter Harwin |
Apogee Therapeutics, Inc. |
Director |
Common Stock |
51.2K |
$1.91M |
$37.26 |
Mar 28, 2024 |
By Tomas Kiselak |
Spyre Therapeutics, Inc. |
Director |
Common Stock |
406K |
$288K |
$0.71 |
Apr 25, 2024 |
By Peter Harwin |
Spyre Therapeutics, Inc. |
Director |
Common Stock |
406K |
$288K |
$0.71 |
Apr 25, 2024 |
By Tomas Kiselak |
Dianthus Therapeutics, Inc. /DE/ |
Director |
Common Stock |
0 |
$0 |
$12.00 |
Sep 27, 2024 |
By Fairmount SPV III, LLC |
Apogee Therapeutics, Inc. |
Director |
Non-Voting Common Stock |
6.74M |
|
|
Mar 28, 2024 |
By Fairmount Healthcare Fund II LP |
Spyre Therapeutics, Inc. |
Director |
Series A Preferred Stock |
346K |
|
|
Apr 25, 2024 |
By Fairmount Healthcare Fund II L.P. |
Viridian Therapeutics, Inc.\DE |
Director, 10%+ Owner |
Series A Non-Voting Convertible Preferred Stock |
133K |
|
|
Mar 28, 2024 |
By Fairmount Healthcare Fund II LP |
Cogent Biosciences, Inc. |
Director |
Series A Convertible Preferred Stock |
67.4K |
|
|
Mar 28, 2024 |
Fairmount Healthcare Fund II LP |
Viridian Therapeutics, Inc.\DE |
Director, 10%+ Owner |
Series B Non-Voting Convertible Preferred Stock |
48.5K |
|
|
Oct 30, 2023 |
By Fairmount Healthcare Fund II LP |
Zenas BioPharma, Inc. |
Director |
Stock Option (Right to Buy) |
37K |
|
|
Sep 12, 2024 |
By Tomas Kiselak |
Spyre Therapeutics, Inc. |
Director |
Series B Preferred Stock |
16.7K |
|
|
Dec 29, 2023 |
By Fairmount Healthcare Fund II L.P. |
Spyre Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
11.3K |
|
|
May 14, 2024 |
By Peter Harwin |
Spyre Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
11.3K |
|
|
May 14, 2024 |
By Tomas Kiselak |
Dianthus Therapeutics, Inc. /DE/ |
Director |
Stock Option (Right to Buy) |
11K |
|
|
May 23, 2024 |
Indirect |
Apogee Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
10.4K |
|
|
Jun 5, 2024 |
Direct |
Apogee Therapeutics, Inc. |
Director |
Common Stock |
0 |
|
|
Mar 28, 2024 |
By Fairmount Healthcare Fund LP |
Apogee Therapeutics, Inc. |
Director |
Non-Voting Common Stock |
0 |
|
|
Mar 28, 2024 |
By Fairmount Healthcare Fund LP |
Cogent Biosciences, Inc. |
Director |
Series A Convertible Preferred Stock |
0 |
|
|
Mar 28, 2024 |
Fairmount Healthcare Fund LP |
Cogent Biosciences, Inc. |
Director |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 10, 2024 |
Fairmount Healthcare Fund II LP |
Viridian Therapeutics, Inc.\DE |
Director, 10%+ Owner |
Series A Non-Voting Convertible Preferred Stock |
0 |
|
|
Mar 28, 2024 |
By Fairmount Healthcare Fund LP |
Zenas BioPharma, Inc. |
Director |
Series A Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
By Fairmount Healthcare Fund II LP |
Zenas BioPharma, Inc. |
Director |
Series B Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
By Fairmount Healthcare Fund II LP |
Zenas BioPharma, Inc. |
Director |
Series C Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
By Fairmount Healthcare Fund II LP |
Zenas BioPharma, Inc. |
Director |
Series Seed Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
By Fairmount Healthcare Fund II LP |